Articles From: Biocept Introduces New Test for Patients With Non-Small Cell Lung Cancer to BioDelivery Sciences Launches InReach Support Program for Those Affected by Opioid Dependence


2015/1/20
SAN DIEGO, Jan.
Sign-up for Biocept Introduces New Test for Patients With Non-Small Cell Lung Cancer investment picks
2015/3/3
SAN DIEGO, March 3, 2015 (GLOBE NEWSWIRE) -- Biocept , Inc. (Nasdaq:BIOC) , a molecular oncology diagnostics company specializing in biomarker analysis in circulating tumor cell (CTC) and circulating tumor DNA (ctDNA), today announced that Michael Nall, Biocept President and CEO, is scheduled to present a corporate overview at the 27th Annual ROTH Conference on March 11, 2015 at The Ritz-Carlton Hotel in Laguna Niguel, California.
Sign-up for Biocept to Present at the 27th Annual ROTH Conference investment picks
2015/1/7
SAN DIEGO, Jan.
Sign-up for Biocept to Present at the 8th Annual OneMedForum investment picks
2015/2/9
SAN DIEGO, Feb.
Sign-up for Biocept, Inc. Prices $10,000,000 Public Offering investment picks
2015/2/25
SAN DIEGO, Feb.
Sign-up for Biocept, Inc. Schedules Webcast and Conference Call for Fourth Quarter 2014 Financial Results investment picks
2015/1/7
SAN DIEGO, Jan.
Sign-up for Biocept's Proprietary Oncology Diagnostics to be Offered on America's Choice Provider Network investment picks
2014/12/15
RESEARCH TRIANGLE PARK, N.C., Dec.
Sign-up for BioCryst Announces Initiation of a Phase 1 Clinical Trial of BCX4430 for the Treatment of Hemorrhagic Fever Viruses investment picks
2014/12/23
RESEARCH TRIANGLE PARK, N.C., Dec.
Sign-up for BioCryst Announces Study Results for BCX4430 in a Non-Human Primate Model of Ebola Virus Infection investment picks
2014/12/18
RESEARCH TRIANGLE PARK, N.C., Dec.
Sign-up for BioCryst Initiates OPuS-2: A Clinical Trial of BCX4161 in Patients With Hereditary Angioedema investment picks
2015/1/5
RESEARCH TRIANGLE PARK, N.C., Jan.
Sign-up for BioCryst Pharmaceuticals Announces the Appointment of Lynne Powell as Chief Commercial Officer investment picks
2014/12/23
RESEARCH TRIANGLE PARK, N.C., Dec.
Sign-up for BioCryst Receives Orphan Drug Designation for BCX4161 for the Treatment of Hereditary Angioedema investment picks
2015/1/14
RESEARCH TRIANGLE PARK, N.C., Jan.
Sign-up for BioCryst Receives Positive Opinion on European Orphan Drug Designation for BCX4161 for the Treatment of Hereditary Angioedema investment picks
2015/2/18
RESEARCH TRIANGLE PARK, N.C., Feb.
Sign-up for BioCryst Reports Fourth Quarter & Full Year 2014 Financial Results investment picks
2015/1/14
BioCryst Pharmaceuticals Inc. shares (BCRX) surged more than 5% in premarket trade, after the company said it received a positive opinion on European orphan drug designation for its treatment for hereditary angioedema.
Sign-up for BioCryst shares rally on positive opinion from Europe for angioedema drug investment picks
2015/2/5
RESEARCH TRIANGLE PARK, N.C., Feb.
Sign-up for BioCryst to Announce 2014 Financial Results February 18 & Present at the 2015 Leerink Global Healthcare Conference investment picks
2015/1/6
RESEARCH TRIANGLE PARK, N.C., Jan.
Sign-up for BioCryst to Present at J.P. Morgan Healthcare Conference investment picks
2015/2/26
RESEARCH TRIANGLE PARK, N.C., Feb.
Sign-up for BioCryst to Present at Two Upcoming Investor Conferences investment picks
2014/12/22
RESEARCH TRIANGLE PARK, N.C., Dec.
Sign-up for BioCryst's RAPIVAB(TM) (peramivir injection) Receives FDA Approval for the Treatment of Acute Uncomplicated Influenza investment picks
2014/12/4
http://www.marketwire.com/library/MwGo/2014/12/4/11G027887/Biodel-Life-Delivered_000-1401197537254.jpg DANBURY, CT--(Marketwired - December 04, 2014) - Biodel Inc. (NASDAQ: BIOD) today announced that the company has initiated enrollment of normal human subjects in a Phase 1 clinical trial of its lyophilized glucagon formulation designed for use in a proprietary auto-reconstitution device intended for the rescue of patients with severe hypoglycemia.
Sign-up for Biodel Initiates Clinical Proof of Concept Study in Glucagon Emergency Management Program investment picks
2015/2/12
DANBURY, CT--(Marketwired - February 12, 2015) - Biodel Inc. (NASDAQ: BIOD) today reported financial results for the first fiscal quarter ended December 31, 2014.
Sign-up for Biodel Reports First Quarter Fiscal Year 2015 Financial Results investment picks
2014/12/17
http://www.marketwire.com/library/MwGo/2014/12/17/11G028774/Biodel-Life-Delivered_000-1401197537254.jpg DANBURY, CT--(Marketwired - December 17, 2014) - Biodel Inc. (NASDAQ: BIOD) today reported financial results for the fourth fiscal quarter ended September 30, 2014.
Sign-up for Biodel Reports Fourth Quarter Fiscal Year 2014 Financial Results investment picks
2015/2/5
http://www.marketwire.com/library/MwGo/2015/2/4/11G032412/biodel-922219161476.jpg DANBURY, CT--(Marketwired - February 05, 2015) - Biodel Inc. (NASDAQ: BIOD) will issue its first quarter fiscal year 2015 financial results on February 12, 2015.
Sign-up for Biodel to Report First Quarter Fiscal Year 2015 Financial Results on February 12, 2015 investment picks
2014/12/10
DANBURY, CT--(Marketwired - December 10, 2014) - Biodel Inc. (NASDAQ: BIOD) will issue its fourth quarter fiscal year 2014 financial results on Wednesday, December 17, 2014.
Sign-up for Biodel to Report Fourth Quarter Fiscal Year 2014 Financial Results on December 17, 2014 investment picks
2015/1/7
http://www.marketwire.com/library/MwGo/2015/1/6/11G029661/Biodel-Life-Delivered_000-1401197537254-220269572145.jpg DANBURY, CT--(Marketwired - January 07, 2015) - Biodel Inc. (NASDAQ: BIOD) announced positive preliminary results from Study 3-151, a Phase 2a clinical trial comparing Biodel's proprietary, concentrated insulin formulation BIOD-531 to Humalog ® Mix 75/25 and Humulin ® R U-500 in patients with type 1 and type 2 diabetes with severe insulin resistance who use at least 150 units of insulin per day or at least 100 units of insulin in a single injection.
Sign-up for Biodel's Concentrated Insulin BIOD-531 Demonstrates Superior Post-Meal Glucose Control Compared to Marketed Prandial/Basal Insulins in Patients With Diabetes Who Require High Doses of Insulin investment picks
2015/1/27
Transaction provides BDSI the opportunity to seek a new partner for ONSOLIS in the U.S., Canada and Mexico RALEIGH, N.C. , Jan.
Sign-up for BioDelivery Sciences Acquires North American Marketing Authorizations for ONSOLIS from Meda investment picks
2014/12/8
Top line data anticipated by end of first quarter 2015 RALEIGH, N.C. , Dec.
Sign-up for BioDelivery Sciences Announces Completion of Randomization in Phase 3 Trial of Clonidine Topical Gel for the Treatment of Painful Diabetic Neuropathy investment picks
2014/12/10
Website and Mobile App Offer Comprehensive Array of Information and Resources to Support Patients and Their Families RALEIGH, N.C. , Dec.
Sign-up for BioDelivery Sciences Launches InReach Support Program for Those Affected by Opioid Dependence investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Biocept Introduces New Test for Patients With Non-Small Cell Lung Cancer to BioDelivery Sciences Launches InReach Support Program for Those Affected by Opioid Dependence
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent